• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

Efficacy of 1% colloidal oatmeal cream was similar to prescription barrier cream in treating mild to moderate atopic dermatitis.

Over the counter (OTC) moisturizer containing 1% colloidal oatmeal was shown to be effective in improving Eczema Area and Severity Index (EASI) scores in Black children after 3 weeks of use,1 Kenvue announced. In 49 children ages 2 to 15 years with mild to moderate atopic dermatitis, the mean change from baseline in EASI score at week 3 was –2.4 (1.7) with the 1% oatmeal cream group compared to a change of –2.1 (2.3) for the prescription barrier cream group.1,2

titikul_b/AdobeStock

titikul_b/AdobeStock

Kenvue reported the findings at the Science of Skincare Summit in Austin, Texas. The company will also be sharing other industry-advancing science, including solutions in cleansing and hydration from Neutrogena.

In The Power of Oat for Sensitive Skin session on September 23 at 2pm CDT, lead author Tonianne Lisante, Kenvue scientific engagement manager, will detail the findings of the peer-reviewed study that was published in the Journal of Dermatological Treatment highlighting 1% colloidal oatmeal cream used at least twice daily for treating atopic dermatitis in Black children.

“When products are not tested in a diverse population, there is a reluctance to accept them as solutions,” Lisante said in a press release. “A previously published randomized study, conducted in children with atopic dermatitis, also known as eczema, the most common chronic inflammatory skin disease, had already established the safety and efficacy of an OTC 1% colloidal oatmeal cream versus a ceramide-based prescription barrier cream in relieving eczema symptoms in children with mild to moderate eczema. Interestingly, the diverse population included in this study provided a new opportunity to conduct a sub analysis among the group of Black subjects, who we know are more effected by eczema, to help advance community health and solve for public health challenges.”1

In the colloidal oatmeal cream group, 100% of patients or participants reported that the cream was appropriate for use on children, and 88% said they would use the cream daily rather than occasionally. Both groups showed improvement in pruritis, skin appearance, dryness/flakiness, and moisturization.2

In her session, Lisante will also review the use of colloidal oatmeal in other products for strengthening the skin’s moisture barrier, soothing irritated skin, and helping to support the microbiome.

References

  1. Kenvue unveils efficacy of colloidal oatmeal in managing atopic dermatitis in Black children and shares new Neutrogena product innovations at Science of Skincare Summit. News release. September 21, 2023. Accessed September 21, 2023. https://www.kenvue.com/kenvue-colloidal-oatmeal-atopic-dermatitis-science-skincare-summit
  2. Lisante TA, Kizoulis M, Nuñez C, Hartman CL. A 1% colloidal oatmeal OTC cream is clinically effective for the management of mild to moderate atopic dermatitis in Black or African American children. J Dermatolog Treat. 2023;34(1):2241587. doi:10.1080/09546634.2023.2241587
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.